Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Genmab, with nine buy ratings, three holds, and one strong-buy rating. The average 12-month price target is $39.50, implying upside from the reported $30.85 share price.
• Genmab exceeded quarterly expectations, reporting $0.54 EPS versus the $0.37 consensus and revenue of $1.16 billion compared with estimates of $1.12 billion.
• Several firms recently upgraded the stock, including Goldman Sachs, BNP Paribas Exane, and TD Cowen; TD Cowen raised its target to $43, while HC Wainwright and Truist Financial set $40 targets.

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen ratings firms that are currently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $39.50.

Several research firms have weighed in on GMAB. The Goldman Sachs Group raised shares of Genmab A/S from a "neutral" rating to a "buy" rating in a research note on Wednesday, April 22nd. HC Wainwright raised their target price on Genmab A/S from $38.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, July 2nd. BNP Paribas Exane upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, April 22nd. Truist Financial assumed coverage on Genmab A/S in a research report on Wednesday, May 27th. They issued a "buy" rating and a $40.00 target price for the company. Finally, TD Cowen raised Genmab A/S from a "hold" rating to a "buy" rating and upped their price target for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $30.85 on Wednesday. The company has a fifty day moving average of $27.56 and a 200-day moving average of $27.97. The firm has a market capitalization of $19.24 billion, a P/E ratio of 24.29, a P/E/G ratio of 1.85 and a beta of 0.83. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. Genmab A/S has a twelve month low of $21.17 and a twelve month high of $35.43.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.37 by $0.17. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. As a group, sell-side analysts anticipate that Genmab A/S will post 1.15 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC grew its position in Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company's stock valued at $25,000 after purchasing an additional 616 shares during the period. NewEdge Advisors LLC increased its stake in Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company's stock valued at $38,000 after purchasing an additional 1,143 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in Genmab A/S during the first quarter worth $34,000. Brown Brothers Harriman & Co. raised its holdings in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company's stock worth $41,000 after buying an additional 780 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its stake in shares of Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock valued at $33,000 after buying an additional 440 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source